Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-24

Study Completion Date

2023-05-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to determine the efficacy of Lidocaine Patch 1.8% in reducing the severity of symptoms in participants with moderate-to-severe pain from Carpal Tunnel Syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

NCT00266214

Carpal Tunnel Syndrome

TERMINATED PHASE3

BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome

NCT05411900

Carpal Tunnel Syndrome Neurogenic Inflammation Pain +2 more

UNKNOWN PHASE2

Local Steroid Injection vs Placebo in Carpal Tunnel Syndrome

NCT02652390

Carpal Tunnel Syndrome

COMPLETED PHASE4

Non-surgical Treatment of Carpal Tunnel Syndrome: Night Splint Versus Local Corticosteroid Infiltration

NCT03196817

Carpal Tunnel Syndrome

UNKNOWN PHASE4

Does it Matter the Volume of Injectate on the Outcome of Ultrasound-guided Perineural Injection for Carpal Tunnel Syndrome

NCT07283874

Carpal Tunnel Syndrome (CTS)

NOT_YET_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, double-blind, cross-over study. Following informed consent, participants fulfilling entry criteria will be randomly assigned into one of two treatment cohorts. Cohort 1 will be treated with active lidocaine study patch for 1 week following FDA approved dosing recommendations, i.e. 12 hours during each 24-hour daily cycle. Following a 1-week washout period, provided participants continue to meet criteria to proceed, they will then be treated with a placebo topical patch for 1 week. A final visit after another 1-week washout period will complete the study. Participants assigned to the Cohort 2 will be evaluated in the same way except they will enter the placebo arm first and then, after 1-week washout, they will enter the active treatment arm, provided to continue to meet criteria to proceed.

For all measures, participants will serve as their own matched control. Comparisons will be made between significant improvements on active versus placebo treatment arms. The first two-week treatment period is Arm 1; the second two-week period is considered the cross-over arm.

Participants failing treatment will be offered standard of care treatment of steroid injection. All participants will wear a brace for the duration of the study per standard clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carpal Tunnel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Participants will serve as their own control

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Double-Blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Lidocaine Patch 1.8% applied to affected hand at night for 2 weeks following FDA approved dosing recommendations, i.e. 12 hours during each 24-hour daily cycle.

Group Type ACTIVE_COMPARATOR

Lidocaine 1.8%

Intervention Type DRUG

Topical Patch

Placebo

Placebo Patch applied to affected hand at night for 2 weeks for 12 hours during each 24-hour daily cycle.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching Placebo Patch

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine 1.8%

Topical Patch

Intervention Type DRUG

Placebo

Matching Placebo Patch

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female participants, 18 years or older at Screening;
* Participants with Carpal Tunnel Syndrome, confirmed by CT6;
* Pain score of at least 4, based on an 11-point numeric rating scale (NRS) (scale of 0-10), at the screening (baseline) visit;
* Able and willing to provide a written informed consent;
* Able and willing to follow study instructions;
* Able and willing to return to clinic for follow-up visits;
* Able and willing to complete a daily diary;
* Intact skin over the affected wrist;
* Woman of childbearing age agreeing to use 2 forms of contraception.

Exclusion Criteria

* Participants must NOT have had prior steroid injection for CTS, CTS surgery, or other intervention/injury to the wrist that might interfere with assessments in the previous 30 days;
* Participants must not have pain at other sites that interfere with their ability to report site-specific pain related to the study (bilateral CT is an exclusion);
* Participants must NOT have cognitive or psychological impairment that interferes with the ability to complete study related assessments;
* Participants with mild (NRS less than 4) or no pain (only numbness) at baseline prior to randomization;
* Opioid tolerance (receiving at least 1 week of oral morphine 60 mg/day OR transdermal fentanyl 25 mcg/hour OR oral oxycodone 30 mg/day OR oral hydromorphone 8 mg/day OR an equianalgesic dose of any other opioid);
* History of sensitivity or allergy to lidocaine or ZTLIDO;
* Irritated, abraded, or otherwise non-intact skin over the affected wrist;
* Concurrently taking tocainide, mexiletine, or local anesthetics;
* Participants with history of or at significant risk for methemoglobinemia;
* Participation in another study of investigational drugs or devices within 30 days before screening, or previous participation in a Lidocaine Patch study;
* Known to or suspected of not being able to comply with the study protocol;
* Any clinically significant condition that would, in the investigator's opinion, preclude study participation for instance alcohol, medication or drug dependency, neurotic personality, psychiatric illness, epilepsy or suicide risk;
* Pregnancy or nursing mother;
* Woman in childbearing age without satisfactory contraception;
* Presence of possible other cause/s for hand pain (i.e., radicular pain, arthritis, injury, surgery) that could confound assessment or self-evaluation of the pain due to Carpal Tunnel Syndrome;
* Participants using topically applied analgesic compounds on the affected area;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes